impact factor, citescore
logo
 

Full Papers

 

HLA-B*51 and its main subtypes in Brazilian patients with Behçet’s disease


1, 2, 3, 4

 

  1. Rheumatology Division, Department of Medicine, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil.
  2. Fleury Group, Research and Development, São Paulo, Brazil.
  3. Rheumatology Division, Department of Medicine, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, and Fleury Group, Research and Development, São Paulo, Brazil.
  4. Rheumatology Division, Department of Medicine, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, and Fleury Group, Research and Development, São Paulo, Brazil. alexandre_wagner@uol.com.br

CER13219
2020 Vol.38, N°5 ,Suppl.127
PI 0053, PF 0059
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 33124572 [PubMed]

Received: 17/02/2020
Accepted : 16/06/2020
In Press: 07/10/2020
Published: 10/12/2020

Abstract

OBJECTIVES:
This study aimed to evaluate the frequency of HLA-B*51 and its subtypes in Brazilian patients with Behçet’s disease (BD) and healthy controls (HC) and to assess possible associations with disease manifestations.
METHODS:
A cross-sectional study with sequential BD patients and HC. HLAB*51 presence was determined by sequence-specific polymerase chain reaction (SSP-PCR) and HLA-B*51 subtypes by the Sanger sequencing method.
RESULTS:
Eighty-three BD patients and 258 HC were evaluated. HLA-B*51 was found in 30.1% of DB patients and in 15.5% of HC (p=0.003). The most prevalent subtypes in DB patients were HLA-B*51:01 (60.0%), HLA-B*51:08 (20.0%), HLA-B*51:22 (8.0%), HLAB* 51:29 (8.0%) and HLA-B*51:02 (4.0%), while HLA-B*51:01 (77.5%) and HLA-B*51:55 (7.5%) were the most prevalent in HC. HLA-B*51 was less frequently found in patients with neurologic involvement (8.0% vs. 29.3%; p=0.034) while HLAB*51:01 was more observed in patients with ocular involvement (93.3% vs. 60.3%; p=0.014). No BD patient with neurologic or vascular involvement presented HLA-B*51:01. HLAB*51:08 was more frequent in patients with vascular manifestations (60.0% vs. 15.4%; p=0.012). In multivariate analysis, HLA-B*51 was an independent risk factor for BD (OR=2.410; 95%CI: 1.332-4.361; p=0.004) and HLA-B*51:08 had an independent association with vascular manifestations of BD (OR = 14.843; 95%CI: 1.550 - 142.115; p=0.019).
CONCLUSIONS:
The prevalence of HLAB*51 is higher in Brazilian BD patients compared to HC, and it is a risk factor for BD. The HLA-B*51:08 subtype was independently associated with vascular manifestations of BD.

Rheumatology Article

Rheumatology Addendum